TORADOL INJ 10MG/ML LIQUID

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Nusipirk tai dabar

Pakuotės lapelis Pakuotės lapelis (PIL)
14-05-2024
Prekės savybės Prekės savybės (SPC)
14-05-2024

Veiklioji medžiaga:

KETOROLAC TROMETHAMINE

Prieinama:

SYNTEX INC.

ATC kodas:

M01AB15

INN (Tarptautinis Pavadinimas):

KETOROLAC

Dozė:

10MG

Vaisto forma:

LIQUID

Sudėtis:

KETOROLAC TROMETHAMINE 10MG

Vartojimo būdas:

INTRAMUSCULAR

Vienetai pakuotėje:

2 TRAYS OF 5X1ML

Recepto tipas:

Prescription

Gydymo sritis:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Produkto santrauka:

Active ingredient group (AIG) number: 0121995001; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

1997-08-26

Pakuotės lapelis

                                IMPORTANT: PLEASE READ
_ _
_ _
_Page 41 of 44_
PART III: CONSUMER INFORMATION
PR
TORADOL
®
ketorolac tromethamine tablets
PR
TORADOL
® IM
ketorolac tromethamine injection
READ THIS INFORMATION EACH TIME YOU REFILL YOUR PRESCRIPTION IN
CASE NEW INFORMATION HAS BEEN ADDED.
THIS LEAFLET IS PART III OF A THREE-PART "PRODUCT MONOGRAPH"
PUBLISHED WHEN TORADOL WAS APPROVED FOR SALE IN CANADA
AND IS DESIGNED SPECIFICALLY FOR CONSUMERS. THIS LEAFLET IS A
SUMMARY DESIGNED SPECIFICALLY FOR YOU. IT WILL NOT TELL YOU
EVERYTHING ABOUT TORADOL.
See your health care provider and
pharmacist regularly and ask them questions about your health and
any medications you take.
ABOUT THIS MEDICATION
WHAT THE MEDICATION IS USED FOR:
TORADOL TABLETS
Your health care provider has prescribed TORADOL tablets for
you for one or more of the following medical conditions:

for short-term use as pain relief after surgery, after labour
or after injury causing muscle or joint pain (not to exceed
5 days for post-surgical patients or 7 days for patients
with musculoskeletal pain)
TORADOL INTRAMUSCULAR INJECTION
Your health care provider has prescribed TORADOL IM for you
for one or more of the following medical conditions:

for short-term use in the hospital for pain relief after
surgery (not to exceed 2 days)
WHAT IT DOES:
TORADOL (ketorolac tromethamine), as a non-steroidal anti-
inflammatory drug (NSAID), can reduce the chemicals produced
by your body which cause pain and swelling.
TORADOL, as a non-steroidal anti-inflammatory drug (NSAID),
does NOT cure your illness or prevent it from getting worse.
TORADOL only can relieve pain and reduce swelling as long as
you continue to take it.
WHEN IT SHOULD NOT BE USED:
DO NOT TAKE TORADOL IF YOU HAVE ANY OF THE FOLLOWING
MEDICAL CONDITIONS:

HAVE HAD OR ARE PLANNING TO HAVE HEART BYPASS SURGERY

HAVE SEVERE, UNCONTROLLED HEART FAILURE

HAVE BLEEDING IN THE BRAIN OR OTHER BLEEDING DISORDERS

ARE AT 28 WEEKS OF PREGNANCY OR MORE

ARE IN LABOUR AND DELIVERY

ARE BREASTFEEDING OR PLAN
                                
                                Perskaitykite visą dokumentą
                                
                            

Prekės savybės

                                _ _
_ _
_Page 1 of 44_
PRODUCT MONOGRAPH
PR
TORADOL
®
ketorolac tromethamine
10 mg tablets
PR
TORADOL
® IM
ketorolac tromethamine injection
10 mg/mL intramuscular injection
Non-Steroidal Anti-Inflammatory Drug (NSAID)
Atnahs Pharma UK Limited
Sovereign House, Miles Gray Road
Basildon, Essex SS14 3FR
United Kingdom
Distributed by: Methapharm Inc.
Brantford, Ontario N3S 7X6
DATE OF PREPARATION:
NOVEMBER 4, 2015 SUBMISSION CONTROL NO: 187985
TORADOL

is a registered trade-mark of Atnahs Pharma UK Limited, used under
license.
_ _
_ _
_Page 2 of 44_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................21
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL PHARMACOLOGY
............................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................27
PART II: SCIENTIFIC INFORMATION
...............................................................................28
PHARMACEUTICAL INFORMATION
..........................................................................28
DETAILED PHARMACOLOGY
.....................................................................................28
TOXICOLOGY
.............................................................
                                
                                Perskaitykite visą dokumentą
                                
                            

Ieškokite perspėjimų, susijusių su šiuo produktu

Peržiūrėti dokumentų istoriją